Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step

Table 2

HLA mismatches and HLA antibodies.

	Group RLP; ()	Group BLP; ()	Group BHP; ()
Number of HLA mismatches per patient (mean ± SD)
Class I (A, B)	2.2 ± 1.2	2.0 ± 1.3	2.7 ± 0.9	n.s.
Class II (DR, DQ)	1.7 ± 0.9	2.5 ± 1.1	2.0 ± 1.2	n.s.
HLA antibody panel reactivity (% PRA) at diagnosis (mean ± SD)
Class I	85 ± 14	50 ± 30	41 ± 20	n.s.
Class II	66 ± 20	63 ± 19	63 ± 28	n.s.
MFI (mean ± SD)
At diagnosis	8539 ± 5478	9747 ± 8363	8467 ± 6876	n.s.
After treatment	8196 ± 5425	7891 ± 6475	5221 ± 4711	n.s.
MFI (mean ± SD)
At diagnosis	11,235 ± 10,116	12,937 ± 11,196	10,657 ± 8973	n.s.
After treatment	12,900 ± 11,018	12,653 ± 12,744	5587 ± 4509	n.s.
Patients with a decrease of [% (count)]
DSAmax	33% (4)	72% (8)	82% (9)	0.036 (group BHP versus RLP)
DSAmax < 500 MFI	8% (1)	9% (1)	18% (2)	n.s.
DSAsum	33% (4)	72% (8)	72% (8)	n.s.

Group RLP, rituximab + low-dose IVIG + plasmapheresis; group BLP, bortezomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose IVIG + plasmapheresis. , donor-specific HLA antibody showing the highest mean fluorescence intensity (MFI) at time of diagnosis. n.s., not significant. in comparison to before treatment. in comparison to before treatment.